胰升糖素样肽-1及类似物的临床研究进展
摘要
胰升糖素样肽-1是由肠道 L 细胞分泌的一种多肽激素。本文将对胰升糖素样肽-1及其类似物的作用机制及在老年2型糖尿病中的应用进展作一综述。
出处
《国外医学（老年医学分册）》
2005年第4期167-171,共5页
Foreign Medical Sciences(Geriatrics)
参考文献22
-
1Carolyn F. Deacon Therapeutic strategies based on glucagon -like peptide 1. Diabetes, 2004; 53:2181～2189
-
2Edwards CM, Stanley SA, Davis R et al. Exendin -4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol, 2001; 281:E155 ～ E161
-
3Harder H, Nielsen L, Thi TDT et al. The effect of liraglutide, a long - acting glucagon - like peptide 1 derivative, on glycemic control, body composition, and 24 - h energy expenditure in patients with type 2 diabetes. Diabetes Care,2004; 27 (8): 1915～1922
-
4Peyot ML, Nolan C J, Soni K et al. Hormone -sensitive lipase has a role in lipid signaling for insulin secretion but is nonessential for the incretin action of glucagon - like peptide 1. Diabetes, 2004; 53:1733～1742
-
5MacDonald PE, Salapatek AMF, Wheeler MB. Glucagon -like peptide - 1 receptor activation antagonizes voltage - dependent repolarizing k+ currents in β - cells. Diabetes,2002; 51:S443 ～S450
-
6Buteau J, Foisy S, Joly E et al. Glucagon - like peptide 1induces pancreatic β - cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes, 2003; 52:124 ～ 132
-
7Li Y, Cao X, Li LX et al. Beta - cell pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon - like peptide - 1. Diabetes, 2005;54 (2): 482～491
-
8Wang Q, Brubaker PL. Glucagon - like peptide - 1 treatment delays the onset of diabetes in 8 week - old db/db mice. Diabetologia, 2002; 45 (9): 1263～1273
-
9Li YZ, Hansotia T, Yusta B et al. Glucagon - like peptide - 1 receptor signaling modulates beta cell apoptosis. J Biol Chem, 2003; 278 (1): 471～478
-
10Szayna M, Doyle ME, Betkey JA et al. Exendin - 4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology, 2000; 141: 1936 ～1941
-
1胰升糖素样肽—1对空腹血糖较低的糖尿病患者更有效（J Clin Endocrin Metab,2001,86：3853—3860）[J].国外医学（内分泌学分册）,2002,22(1):60-60.
-
2胡圆圆,叶山东.DPP－4抑制剂不良反应[J].药品评价,2011,8(21):46-49. 被引量：1
-
3李龙英,肖谦.胰升糖素样肽-1与β细胞量[J].国际内分泌代谢杂志,2006,26(B04):65-67. 被引量：1
-
4朱敏,史虹莉,方京冲,李智,胡敏,黄葵香.Exendin-4对非糖尿病小鼠的血糖和糖耐量的影响[J].中国新药与临床杂志,2005,24(1):18-20. 被引量：1
-
5董凌燕,刘超,张梅,刘翠萍,覃又文.胰升糖素样肽-1对胰岛β细胞胰岛素基因表达的调节作用[J].江苏医药,2006,32(1):45-46. 被引量：2
-
6宁光.利拉鲁肽对胃肠道作用的机制探讨[J].中华内分泌代谢杂志,2012,28(11). 被引量：8
-
7诺和诺德公司新医药产品介绍[J].国外医学（内分泌学分册）,2003,23(3):187-188.
-
8詹宇红.基于胰升糖素样肽-1的治疗进展[J].医学研究杂志,2008,37(8):116-118.
-
9牟波.胰升糖素样肽-1及其类似物的降糖机制研究进展[J].国外医学（内分泌学分册）,2003,23(B04):4-6. 被引量：10
-
10Ole Schmitz.治疗2型糖尿病的新药[J].国外医学（内分泌学分册）,2005,25(3):186-188. 被引量：2
